WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510279
Description: GW9508 is a GPR40 agonist. GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. GW9508 also inhibits insulin secretion by activating ATP-sensitive potassium channels in rat pancreatic β-cells.
MedKoo Cat#: 510279
Chemical Formula: C22H21NO3
Exact Mass: 347.15214
Molecular Weight: 347.41
Elemental Analysis: C, 76.06; H, 6.09; N, 4.03; O, 13.82
Synonym: GW9508; GW-9508; GW 9508.
IUPAC/Chemical Name: 3-(4-((3-phenoxybenzyl)amino)phenyl)propanoic acid
InChi Key: DGENZVKCTGIDRZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)
SMILES Code: O=C(O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1
Appearance: white to off-white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 347.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Philippe C, Wauquier F, LÃ©otoing L, Coxam V, Wittrant Y. GW9508, a free fatty acid receptor agonist, specifically induces cell death in bone resorbing precursor cells through increased oxidative stress from mitochondrial origin. Exp Cell Res. 2013 Nov 15;319(19):3035-41. doi: 10.1016/j.yexcr.2013.08.013. Epub 2013 Aug 22. PubMed PMID: 23973666.
2: Zhao YF, Wang L, Zha D, Qiao L, Lu L, Yu J, Qu P, Sun Q, Qiu J, Chen C. GW9508 inhibits insulin secretion by activating ATP-sensitive potassium channels in rat pancreatic β-cells. J Mol Endocrinol. 2013 Jun 1;51(1):69-77. doi: 10.1530/JME-13-0019. Print 2013. PubMed PMID: 23628491.
3: Fujita T, Matsuoka T, Honda T, Kabashima K, Hirata T, Narumiya S. A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. J Invest Dermatol. 2011 Aug;131(8):1660-7. doi: 10.1038/jid.2011.123. Epub 2011 May 19. PubMed PMID: 21593768.
4: Lu SY, Jiang YJ, Zou JW, Luo HB, Wu TX. Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: a combined QM/MM study and pharmacophore modeling. J Mol Graph Model. 2011 Apr;29(6):818-25. doi: 10.1016/j.jmgm.2011.01.006. Epub 2011 Feb 1. PubMed PMID: 21334233.